BVC COP

Pfizer Inc. (PFE.CL)

Compare
109,420.00
-2,420.00
(-2.16%)
At close: January 24 at 10:19:19 AM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
59,375,000.00
58,496,000.00
100,330,000.00
81,288,000.00
41,651,000.00
Cost of Revenue
19,505,000.00
24,954,000.00
34,344,000.00
30,821,000.00
8,484,000.00
Gross Profit
39,870,000.00
33,542,000.00
65,986,000.00
50,467,000.00
33,167,000.00
Operating Expense
30,827,000.00
30,183,000.00
28,714,000.00
26,763,000.00
24,338,000.00
Operating Income
9,043,000.00
3,359,000.00
37,272,000.00
23,704,000.00
8,829,000.00
Net Non Operating Interest Income Expense
-2,057,000.00
-585,000.00
-987,000.00
-1,255,000.00
-1,376,000.00
Other Income Expense
-3,080,000.00
-1,716,000.00
-1,556,000.00
1,763,000.00
-415,000.00
Pretax Income
3,904,000.00
1,058,000.00
34,729,000.00
24,311,000.00
7,036,000.00
Tax Provision
-402,000.00
-1,115,000.00
3,328,000.00
1,852,000.00
370,000.00
Net Income Common Stockholders
4,252,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Diluted NI Available to Com Stockholders
4,252,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Basic EPS
0.76
0.38
5.59
3.92
1.73
Diluted EPS
0.75
0.37
5.47
3.85
1.71
Basic Average Shares
5,658,750.00
5,643,000.00
5,608,000.00
5,601,000.00
5,555,000.00
Diluted Average Shares
5,658,750.00
5,643,000.00
5,733,000.00
5,708,000.00
5,632,000.00
Total Expenses
50,332,000.00
55,137,000.00
63,058,000.00
57,584,000.00
32,822,000.00
Net Income from Continuing & Discontinued Operation
4,252,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Normalized Income
8,667,980.00
5,997,890.00
35,039,856.00
24,999,276.00
8,205,548.32
Interest Income
983,000.00
1,624,000.00
251,000.00
36,000.00
73,000.00
Interest Expense
3,040,000.00
2,209,000.00
1,238,000.00
1,291,000.00
1,449,000.00
Net Interest Income
-2,057,000.00
-585,000.00
-987,000.00
-1,255,000.00
-1,376,000.00
EBIT
6,944,000.00
3,267,000.00
35,967,000.00
25,602,000.00
8,485,000.00
EBITDA
13,836,000.00
9,557,000.00
41,031,000.00
30,793,000.00
13,262,000.00
Reconciled Cost of Revenue
17,807,000.00
23,397,000.00
32,889,000.00
29,330,000.00
7,055,000.00
Reconciled Depreciation
6,892,000.00
6,290,000.00
5,064,000.00
5,191,000.00
4,777,000.00
Net Income from Continuing Operation Net Minority Interest
4,274,000.00
2,134,000.00
31,366,000.00
22,413,000.00
6,630,000.00
Total Unusual Items Excluding Goodwill
-5,562,000.00
-4,891,000.00
-4,064,000.00
-2,799,000.00
-1,663,000.00
Total Unusual Items
-5,562,000.00
-4,891,000.00
-4,064,000.00
-2,799,000.00
-1,663,000.00
Normalized EBITDA
19,398,000.00
14,448,000.00
45,095,000.00
33,592,000.00
14,925,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,168,020.00
-1,027,110.00
-390,144.00
-212,724.00
-87,451.68
-

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GS71.DU GSK PLC
16.62
+2.85%
 
AMG.HA Amgen Inc
260.05
-0.55%
 
0O59.IL Sanofi
102.10
+2.03%
 
AMGN.MX Amgen Inc.
5,660.00
0.00%
 
BAYA.BE Bayer AG
5.25
+0.96%
 
SNW.F Sanofi
101.82
+1.78%
 
4503.T Astellas Pharma Inc.
1,518.50
+1.10%
 
NOTA.DU Novartis AG
96.80
+1.89%
 
1LLY.MI Eli Lilly and Co
743.60
-0.31%
 
ZEG.DE AstraZeneca PLC
131.90
+0.11%